Literature DB >> 30877305

Noninvasive Assessment of Myocardial Perfusion in Different Blood Pressure Phenotypes and Its Association With Arterial Stiffness Indices.

Panagiota Anyfanti1, Eugenia Gkaliagkousi1, Areti Triantafyllou1, Konstantina Dipla2, Hippocrates Zarifis1, Polyvios Arseniou1, Antonios Lazaridis1, Stella Douma1.   

Abstract

BACKGROUND: We investigated for the first time whether patients with recent-onset, uncomplicated hypertension and different hypertension phenotypes exhibit altered values of subendocardial viability ratio (SEVR), a surrogate measure of myocardial perfusion that correlates with the ratio of subendocardial to subepicardial blood flow. We additionally explored whether SEVR correlates with arterial stiffness in a population free from the long-term effects of essential hypertension.
METHODS: Nontreated individuals free from any known health problems were classified as true hypertensives (THs), white-coat hypertensives (WCHs), masked hypertensives (MHs), and normotensives. SEVR was noninvasively calculated with applanation tonometry in the radial artery. Carotid-femoral pulse wave velocity, central and peripheral pulse pressure (PP), augmentation index, and central systolic/diastolic blood pressure (BP) were assessed with applanation tonometry. Total arterial compliance index was calculated with impedance cardiography.
RESULTS: In a total of 150 participants, normotensive individuals exhibited the highest values of SEVR (162.9 ± 25.3%), whereas SEVR appeared to be similar in MHs (150.2 ± 22.1%), WCHs (148.1 ± 20.4%), and THs (149.9 ± 24.8%) (P = 0.017). In the univariate analysis, SEVR significantly correlated with central systolic BP, peripheral PP, and total arterial compliance index. The association between SEVR and both central (P = 0.017) and peripheral PP (P = 0.003) remained significant after adjustment for heart rate and other parameters.
CONCLUSIONS: SEVR, an alternative tool to the invasive assessment of microvascular coronary perfusion, presents different values across patients with divergent BP phenotypes and correlated with arterial stiffness, even in the absence of overt cardiovascular disease. Future studies need to address the potential utility of this easily implementable marker as a screening test for myocardial ischemia. © American Journal of Hypertension, Ltd 2019. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  arterial stiffness; blood pressure; hypertension; masked hypertension; myocardial perfusion; subendocardial viability ratio; white-coat hypertension

Year:  2019        PMID: 30877305     DOI: 10.1093/ajh/hpz039

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  4 in total

1.  Similar Myocardial Perfusion and Vascular Stiffness in Children and Adolescents with High Lipoprotein (a) Levels, in Comparison with Healthy Controls.

Authors:  Kyriaki Papadopoulou-Legbelou; Areti Triantafyllou; Olga Vampertzi; Nikolaos Koletsos; Stella Douma; Efimia Papadopoulou-Alataki
Journal:  Pulse (Basel)       Date:  2021-09-10

2.  Skin microvascular function, as assessed with laser speckle contrast imaging, is impaired in untreated essential and masked hypertension.

Authors:  Antonios Lazaridis; Areti Triantafyllou; Konstantina Dipla; Panagiotis Dolgyras; Nikolaos Koletsos; Panagiota Anyfanti; Spyros Aslanidis; Stella Douma; Eugenia Gkaliagkousi
Journal:  Hypertens Res       Date:  2021-12-16       Impact factor: 3.872

3.  Assessment of vascular damage in children and young adults with Familial Mediterranean Fever.

Authors:  Olga Vampertzi; Kyriaki Papadopoulou-Legbelou; Areti Triantafyllou; Nikolaos Koletsos; Sofia Alataki; Stella Douma; Efimia Papadopoulou-Alataki
Journal:  Rheumatol Int       Date:  2021-11-05       Impact factor: 2.631

4.  Impaired subendocardial perfusion in patients with metabolic syndrome.

Authors:  Francesco Fantin; Anna Giani; Ludovico Gasparini; Andrea P Rossi; Elena Zoico; Gloria Mazzali; Mauro Zamboni
Journal:  Diab Vasc Dis Res       Date:  2021 Nov-Dec       Impact factor: 3.291

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.